vTv Therapeutics Inc.
NASDAQ:VTVT
Overview | Financials
Company Name | vTv Therapeutics Inc. |
Symbol | VTVT |
Currency | USD |
Price | 13.87 |
Market Cap | 36,232,046 |
Dividend Yield | 0% |
52-week-range | 7.38 - 30.99 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Paul J. Sekhri M.Sc., MSc |
Website | https://www.vtvtherapeutics.com |
An error occurred while fetching data.
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD